Journals / MN Kardiyoloji / 2008 / Cilt: 15 - Sayı: 2

Action mechanisms of statins and early statin therapy in acute coronary syndrome

Statinlerin etki mekanizmaları ve akut koroner sendromda statin kullanımı

Pages
138–145
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review will present the efficacy of early statin therapy in patients with acute coronary syndrome in addition to conventional medical therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute coronary syndrome (ACS), which is associated with high rates of morbidity and mortality, refers to the spectrum of acute myocardial ischemia, including unstable angina (UA), ST-segment elevated myocardial infarction and acute myocardial infarction without ST-segment elevation.
📊
Key Findings & Data:Although significant therapeutic advances in the treatment of ACS have been made with antiplatelet and antithrombotic therapy, these alone do not appear to completely stabilize unstable plaques.
💡
Conclusion & Impact:This review will present the efficacy of early statin therapy in patients with acute coronary syndrome in addition to conventional medical therapy
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Ateroskleroz · Farmakolojik etkiler · Akut koroner sendrom

Abstract

Acute coronary syndrome (ACS), which is associated with high rates of morbidity and mortality, refers to the spectrum of acute myocardial ischemia, including unstable angina (UA), ST-segment elevated myocardial infarction and acute myocardial infarction without ST-segment elevation. Atherothrombosis is the major cause of ACS. It has now become clear that coronary atherosclerosis is not simply an inevitable consequence of aging but rather a chronic inflammatory process that can be converted into an acute clinical event by plaque rupture and arterial thrombosis. The rupture of an unstable atherosclerotic plaque results in the lipid core coming into contact with circulating blood, which triggers platelet activation and coagulation, leading to thrombosis. Although significant therapeutic advances in the treatment of ACS have been made with antiplatelet and antithrombotic therapy, these alone do not appear to completely stabilize unstable plaques. This review will present the efficacy of early statin therapy in patients with acute coronary syndrome in addition to conventional medical therapy

Özet

Akut koroner sendrom (AKS); anstabil (kararsız) angina pektoris, ST segment yükselmeli-yükselmesiz miyokard infarktüsü gibi yüksek morbidite ve mortalite ile seyreden klinik durumları kapsayan bir tanımdır. AKS gelişimde rol oynayan en önemli faktör aterosklerotik plak zeminininde gelişen aterotrombozdur. Günümüzde koroner aterosklerozun yalnızca erken yaşlarda başlayan yağlı çizgilenmelerin zamanla artışına bağlı pasif bir olay olmayıp aynı zamanda dinamik inflamatuar bir süreç olduğu bilinmektedir. İnflamasyonun yoğun olduğu, lipidden zengin, ince fibröz kapsülle çevrili kararsız plağın rüptürü sonucunda plak içeriğinin kanla temas etmesi platelet agregasyonunu ve koagülasyonu tetikleyerek tromboz oluşumuna yol açar. Bu nedenle platelet fonksiyonlarına, koagülasyon kaskadına ve kardiyak arz-talep dengesine yönelik geleneksel tedavi iskeminin süre ve boyutunu etkilemekle birlikte, altta yatan aterosklerotik hastalığın tedavisine yönelik bir etkisi bulunmamaktadır. Bu veriler ışığında AKS gelişimden sorumlu dinamik inflamatuar plağın stabilize edilmesine, altta yatan aterosklerotik hastalığın durdurulması veya geriletilmesine yönelik yeni tedavi stratejilerinin geliştirilmesine ihtiyaç vardır. Bu derlememizde akut koroner sendromda uygulanan konvansiyonel tedavi stratejilerine ek olarak lipid düşürücü, anti inflamatuar, antiagregan ve endotel fonksiyonlarını iyileştirici etkileri olan statinlerin rolü irdelenecektir.

🔖

Cite This Article

SÖZEN, B., ALBAYRAK, E. S., YAZICI, M. (2008). Action mechanisms of statins and early statin therapy in acute coronary syndrome. MN Kardiyoloji, Cilt: 15 - Sayı: 2, 138–145. https://ajindex.com/articles/297970

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9. 2.Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hyperc-holesterolemia. N Engl J Med 1995;333:1301-7. 3.Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22. 4.Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22. 5.Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:l-10. 6.Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol, homeostasis. Science 986; 232: 34-47. 7.Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5. 8.Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70. 9.Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8. 10.Li J-J. Rapid effects on lipid profile and C-reactive protein by simvastatin in patients with hypercholesterolemia. Clin. Cardiol 2003;26:472-6. 11.Li J-J, Fang C-H. Effect of a single high-dose of simvastatin on C-reactive protein in patients with unstable angina. HeartDrug 2004;4 12.Laufs U, La Fata J, Plutzky J, Liao JK. Upregulation of en-dothelial nitric oxide synthase by HMG CoA reductase in-hibitors.Circulationl998;97:1129-35. 13.Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin Invest 1998; 101: 2711-9. 14.Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002;54:395-